Ding and colleagues at the University of Virginia provide an analysis of 444 patients who had stereotactic radiosurgery for an arteriovenous malformation (AVM) without evidence of prior symptomatic hemorrhage.
We thank Dr. Kondziolka for his insightful comments regarding our paper on unruptured AVMs. Arteriovenous malformations represent a relatively rare but complicated vascular pathology for which the treatment will always involve a multidisciplinary approach. 4, 6 Our bias is to aggressively treat unruptured AVMs that present in young patients using microsurgery, radiosurgery, embolization, or a combination of these techniques.
Dr. Kondziolka mentioned that there was a high proportion of superficial AVMs (86%) in our series. In fact, some of the patients in our series had superficially located AVMs that were in eloquent areas; they were offered radiosurgery. Stapf et al. 7 noted deep location to be an independent predictor of AVM rupture, which may explain the relatively low proportion of unruptured deep AVMs in our series. In our experience, a patient with an unruptured and asymptomatic AVM most often chooses radiosurgery over the alternatives of microsurgery or embolization. Patients perceive radiosurgery as an attractive approach conferring a reasonable chance of benefiting them while
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at the same time exposing them to only rare upfront risks and generally infrequent as well as manageable long-term risks. Based on our results, radiosurgery seems warranted given its relatively favorable results, the high cumulative lifetime AVM hemorrhage risk in the absence of obliteration, and the known morbidity and mortality associated with rupture.
1,2
We acknowledge the significant undertaking of the ARUBA trial and hope that it can be completed. 3, 5 The results from this prospective study are highly anticipated by the cerebrovascular community and could affect the way we treat and counsel patients harboring unruptured AVMs. However, in the event that ARUBA fails to attain adequate patient accrual, the next best study may be a prospective registry such as the National Neurosurgery Quality and Outcomes Database (N 2 QOD). A prospective registry detailing radiosurgical treatment outcomes of unruptured AVMs would allow us to observe their behavior and risk-benefit profile over time. The ultimate goal is to settle the controversy regarding the optimal management algorithm for patients with unruptured AVMs.
